Mofecet (Bupivacaine Hydrochloride Monohydrate)

Mofecet (bupivacaine) is used in clinical settings that require regional nerve blockade for surgical and obstetric care.

• Spinal anesthesia: provides dense sensory and motor block for lower‑body surgeries, facilitating operative conditions and patient comfort.
• Postoperative analgesia: extends pain relief after surgery when administered intrathecally, reducing the need for systemic opioids.
• Labor analgesia: offers effective pain control during childbirth while preserving maternal motor function.

• Bupivacaine exerts its anesthetic effect by reversibly binding to the intracellular portion of voltage‑gated sodium channels in neuronal membranes. This binding stabilizes the channel in an inactive state, preventing sodium influx during depolarization and thereby blocking the propagation of nerve impulses. The result is a reversible loss of sensation in the targeted region without affecting cardiovascular conduction at therapeutic concentrations.

Intrathecal bupivacaine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Transient hypotension: mild drop in blood pressure shortly after injection.
• Bradycardia: slower heart rate that may require monitoring.
• Nausea or vomiting: gastrointestinal upset following the procedure.
• Pruritus: localized itching at the injection site or generalized.
• Headache: post‑dural puncture headache in some patients.

Serious or Rare Side Effects

• Cardiac arrhythmia: potentially life‑threatening rhythm disturbances.
• Central nervous system toxicity: seizures, confusion, or loss of consciousness.
• Persistent motor block: prolonged weakness beyond expected duration.
• Epidural hematoma: bleeding in the spinal canal causing neurological compromise.
• Allergic reaction: urticaria, bronchospasm, or anaphylaxis.

When using Mofecet, clinicians should observe specific precautions to minimize risks and ensure optimal outcomes.

• Patient assessment: evaluate cardiovascular and respiratory status before administration.
• Dose calculation: tailor the intrathecal dose to patient weight, age, and comorbidities.
• Monitoring: continuously observe blood pressure, heart rate, and oxygen saturation during and after injection.
• Contraindications: avoid use in patients with known hypersensitivity to amide local anesthetics.
• Neurological evaluation: assess for signs of spinal cord injury or infection prior to the procedure.
• Store below 25°C: keep in the original container, protect from light and moisture.

Bupivacaine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may increase cardiotoxicity.
• Beta‑blockers (e.g., propranolol): can exacerbate bradycardia and hypotension.
• Calcium channel blockers (e.g., verapamil): additive depressant effects on cardiac conduction.

Moderate Interactions (Monitor Closely)

• Opioids (e.g., fentanyl): synergistic respiratory depression.
• Sedatives or hypnotics (e.g., midazolam): enhanced central nervous system depression.
• MAO inhibitors: potential for prolonged anesthetic effect.